Winston Pharmaceuticals (Winston Pharmaceuticals) Change In Working Capital : $-1.35 Mil (TTM As of Mar. 2010)

View and export this data going back to 2006. Start your Free Trial

What is Winston Pharmaceuticals Change In Working Capital?

Winston Pharmaceuticals's change in working capital for the quarter that ended in Mar. 2010 was $-0.46 Mil.

Winston Pharmaceuticals's change in working capital for the fiscal year that ended in Dec. 2009 was $-1.65 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Winston Pharmaceuticals Change In Working Capital Historical Data

The historical data trend for Winston Pharmaceuticals's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Winston Pharmaceuticals Change In Working Capital Chart

Winston Pharmaceuticals Annual Data

Trend

Sep05

Sep06

Sep07

Dec08

Dec09

Change In Working Capital

0.06

0.30

-0.01

2.07

-1.65

Winston Pharmaceuticals Quarterly Data
	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10
Change In Working Capital	Get a 7-Day Free Trial														-0.76	-0.49	-0.16	-0.24	-0.46

Winston Pharmaceuticals Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2010 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.35 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Winston Pharmaceuticals Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Winston Pharmaceuticals's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Winston Pharmaceuticals (Winston Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Winston Pharmaceuticals Inc (GREY:WPHM) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 North Fairway Drive, Suite 134, Vernon Hills, IL, USA, 60061

Website

http://www.winstonlabs.com

Winston Pharmaceuticals Inc is a pharmaceutical company, which is engaged in the discovery and development of products for pain management. The company focuses on major pain indications such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo- and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease.

Executives

Frost Phillip Md Et Al	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Frost Gamma Investments Trust	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137
Subbarao V Uppaluri	director	4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137
Curtis Lockshin	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Glenn L Halpryn	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Steven Jerry Glauser	10 percent owner	1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Noah M Silver	director, officer: Vice President	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Alan Jay Weisberg	director, officer: Chief Financial Officer	2500 NORTH MILITARY TRAIL, SUITE 206, BOCA RATON FL 33431
Stephen Bittel	10 percent owner	4400 BISCAYNE BOULEVARD SUITE 950 MIAMI FL 33137

Winston Pharmaceuticals (Winston Pharmaceuticals) Headlines

No Headlines